FDA Approval Sought for Selinexor in DLBCL

December 23, 2019 – Karyopharm Therapeutics Inc., has submitted a new drug application (NDA) to the FDA for selinexor for the treatment of patients with relapsed/refractory diffuse large B-Cell lymphoma (DLBCL) who have received at least 2 prior multiagent therapies and who are ineligible for stem cell transplantation, including CAR T-cell therapy. “Earlier this year we reported compelling results from the phase IIb SADAL study investigating selinexor in patients with … (leggi tutto)